SCHEMBL3316449

SCHEMBL3316449

COc1cc(NC(=O)N(Cc2ccccc2)C2=COCO2)ccc1-n1ccnc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 2/20 0.47
CYP19A1 P11511 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
UBE2M P61081 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3318296 0.87 BLM (0.43) HTTMEN1KMT2AUBE2MDCUN1D1
SCHEMBL4449706 0.73 AAK1 (0.65) AAK1CYP19A1CYP11B1CYP11B2HTT
SCHEMBL4920592 0.72 MAPT (0.42) HTTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4354386 0.72 CCR2 (0.41) MEN1KMT2AALDH1A1MAPTUBE2M
SCHEMBL4359232 0.72 ACHE (0.39) TSHRSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL3316441 0.72 KMT2A (0.56) AAK1TSHRHTTSMN1; SMN2MEN1
SCHEMBL5649471 0.72 CCNT1 (0.52) ALOX15TSHRALDH1A1
SCHEMBL4351294 0.71 ALDH1A1 (0.39) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL4359597 0.70 LMNA (0.42) HTTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4347969 0.70 EGFR (0.43) MEN1KMT2AALDH1A1MAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105904-A1 UREA TYPE CINNAMIDE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-04-29 US disclosed
EP-2019093-A1 UREA TYPE CINNAMIDE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2009-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105904-A1 UREA TYPE CINNAMIDE DERIVATIVE SLC14A1, UTS2R, MAN2B1 AAK1 2344/4885CYP19A1 1348/4885CYP11B1 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.